Momenta reports Phase I data for anti-FCRN mAb

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) said its immune-mediated disease candidate M281 was safe and showed proof of mechanism in a Phase I trial in healthy volunteers. M281 is a human IgG1 mAb against neonatal Fc receptor (FCRN; FCGRT).

Momenta said multiple ascending doses of M281 reduced circulating levels of IgG antibodies by up to 89% over the 98-day study, while single ascending doses of M281 reduced the measure by up to 80%. M281 was well tolerated with no serious adverse events reported. The double-blind, placebo-controlled, Dutch trial enrolled 50 healthy volunteers...